Why did MOLN.SW stock fall pre-market today?

The pre-market drop followed profit-taking and sector weakness in healthcare. Elevated volume at **31,341** shares amplified the move. Short-term traders reacted to mixed pipeline signals and broader biotech sentiment.

What are the key valuation metrics for MOLN.SW stock?

Molecular Partners shows **EPS -1.65**, **PE -2.03**, **PB 1.56**, and cash per share **CHF 2.49**. The balance sheet appears conservative, while earnings remain negative.

What price targets should investors use for MOLN.SW stock?

A conservative target is **CHF 2.35** (Meyka yearly forecast). A base technical target is **CHF 3.70**, with upside near the year high **CHF 4.14**. Adjust targets to your risk profile.

When is the next earnings or clinical update that could move MOLN.SW stock?

The next earnings announcement is scheduled for **2026-05-12**. Clinical readouts and partner news may arrive ahead of that date and trigger volatility.

CH Stocks

MOLN.SW Molecular Partners (SIX) pre-market -7.20% CHF3.35 24 Mar 2026: outlook

ByHuzaifa Zahoor March 24, 2026March 24, 2026

The MOLN.SW stock opened weaker in pre-market trade, down 7.20% to CHF 3.35 on the SIX exchange on 24 Mar 2026. Volume is elevated at 31,341 shares versus an average of 25,737. Investors are pricing fresh downside after a recent run of mixed trial updates and sector weakness. This note summarises price action, valuation, technical signals, and near-term catalysts for Molecular Partners AG (MOLN.SW stock) from a market-analysis perspective.